Shanghai Hutchison Pharmaceuticals Limited

China

Back to Profile

1-6 of 6 for Shanghai Hutchison Pharmaceuticals Limited Sort by
Query
Aggregations
Jurisdiction
        World 4
        United States 2
Date
2025 (YTD) 1
2022 1
2021 2
2020 2
IPC Class
C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings 3
C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings 2
A61K 36/752 - Citrus, e.g. lime, orange or lemon 1
A61K 36/9068 - Zingiber, e.g. garden ginger 1
A61K 9/20 - Pills, lozenges or tablets 1
See more
Found results for  patents

1.

PATCHOULI QI-RECTIFYING TABLET AND PREPARATION PROCESS THEREFOR, AND QUANTITATIVE AND QUALITATIVE DETERMINATION METHOD FOR MULTIPLE COMPONENTS IN PATCHOULI QI-RECTIFYING TABLET

      
Application Number CN2023111932
Publication Number 2025/025254
Status In Force
Filing Date 2023-08-09
Publication Date 2025-02-06
Owner SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (China)
Inventor
  • Shen, Danping
  • Zhan, Changsen
  • Zhang, Zhengguang

Abstract

A patchouli Qi-rectifying tablet, and a preparation method therefor and a qualitative and quantitative determination method therefor. The patchouli Qi-rectifying tablet comprises the following components in parts by mass: 0.5-1.5 parts of patchouli oil; 0.1-1 part of perilla leaf oil; 150-250 parts of common aucklandia root; 100-150 parts of rhizome of swordlike atractylodes; 10-100 parts of root of Ural licorice; 150-250 parts of Indian bread; 100-150 parts of dried tangerine peel; 100-150 parts of prepared tuber of pinellia; 100-150 parts of officinal magnolia bark; and 100-150 parts of fresh ginger. The qualitative and quantitative determination method for multiple components in the patchouli Qi-rectifying tablet comprises: performing qualitative determination of ten components, i.e., liquiritin, hesperidin, honokiol, costunolide, dehydrocostus lactone, magnolol, atractylodin, perilla ketone, nobiletin, and tangeretin, in the patchouli Qi-rectifying tablet; and performing quantitative determination of seven components, i.e., liquiritin, hesperidin, honokiol, costunolide, dehydrocostus lactone, magnolol, and atractylodin, in the patchouli Qi-rectifying tablet. According to the method, the operation is simple, the detection time is short, the linear relationship is good, the repeatability is good, the precision is high, the accuracy is high, and the stability is good.

IPC Classes  ?

  • A61K 36/9068 - Zingiber, e.g. garden ginger
  • G01N 30/02 - Column chromatography
  • A61K 9/20 - Pills, lozenges or tablets
  • A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
  • A61P 11/00 - Drugs for disorders of the respiratory system
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
  • A61P 1/12 - Antidiarrhoeals
  • A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

2.

Preparation method of a glycoside compound

      
Application Number 17762387
Grant Number 12398168
Status In Force
Filing Date 2021-01-04
First Publication Date 2022-12-01
Grant Date 2025-08-26
Owner SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (China)
Inventor
  • Zhan, Changsen
  • Tian, Ping
  • Cui, Chunxiao
  • Zhang, Jiange
  • Zhou, Junjie
  • Lin, Guoqiang
  • Xu, Wenwen
  • Zhang, Zhengguang

Abstract

Preparation method of glycoside compounds is involved in the invention, with the advantages of short synthesis steps, high stereoselectivity and yield, simple production operation, low equipment requirements, environmental protection and suitability for industrial mass production.

IPC Classes  ?

3.

METHOD FOR PREPARING GLYCOSIDE COMPOUND

      
Application Number CN2021070109
Publication Number 2021/139621
Status In Force
Filing Date 2021-01-04
Publication Date 2021-07-15
Owner SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (China)
Inventor
  • Zhan, Changsen
  • Tian, Ping
  • Cui, Chunxiao
  • Zhang, Jiange
  • Zhou, Junjie
  • Lin, Guoqiang
  • Xu, Wenwen
  • Zhang, Zhengguang

Abstract

The present invention relates to a method for preparing a glycoside compound, having a short synthesis process, a single product configuration, high selectivity, high yield, simple production and operation, and low equipment requirements, and being environmentally friendly and suitable for large-scale industrial production.

IPC Classes  ?

  • C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings

4.

Glycoside compound and preparation method therefor, composition, application, and intermediate

      
Application Number 17054124
Grant Number 11325937
Status In Force
Filing Date 2019-05-07
First Publication Date 2021-04-22
Grant Date 2022-05-10
Owner SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (China)
Inventor
  • Lin, Guoqiang
  • Zhang, Jiange
  • Tian, Ping
  • Feng, Chenguo
  • Zhan, Changsen
  • Zhou, Junjie

Abstract

The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

IPC Classes  ?

  • C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
  • C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
  • C07H 5/10 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium, or tellurium to sulfur

5.

TRADITIONAL CHINESE MEDICINE COMPOSITION, AND PREPARATION AND USE THEREOF

      
Application Number CN2018100211
Publication Number 2020/010664
Status In Force
Filing Date 2018-08-13
Publication Date 2020-01-16
Owner
  • SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (China)
  • SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (China)
Inventor
  • Zhou, Junjie
  • Yang, Li
  • Zhan, Changsen
  • Yu, Jiejing
  • Shen, Danping
  • Ding, Lili
  • Wang, Zhengtao

Abstract

Disclosed are a traditional Chinese medicine composition that can protect the liver and promote bile secretion, and the preparation and use thereof. The effective ingredient raw materials of the traditional Chinese medicine composition comprise: Polygoni cuspidati rhizoma et radix, Citri reticulatae pericarpium viride, Crataegi fructus and rhubarb. The traditional Chinese medicine composition and an extract thereof can significantly reduce serum ALT, AST, ALP, T-Bil, D-Bil and TBA, significantly reduce hepatocyte necrosis, ameliorate hepatocyte swelling, cytoplasm rarefaction, ballooning degeneration and feathering degeneration, and reduce inflammatory cell infiltration, thereby preventing or treating cholestasis.

IPC Classes  ?

  • A61K 36/752 - Citrus, e.g. lime, orange or lemon
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

6.

GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE

      
Application Number CN2019085823
Publication Number 2020/001166
Status In Force
Filing Date 2019-05-07
Publication Date 2020-01-02
Owner SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (China)
Inventor
  • Lin, Guoqiang
  • Zhang, Jiange
  • Tian, Ping
  • Feng, Chenguo
  • Zhan, Changsen
  • Zhou, Junjie

Abstract

Disclosed are a glycoside compound represented by formula (III) and a preparation method therefor, a composition, an application, and an intermediate. The provided glycoside compound is simple in preparation method, can remarkably improve expression of VEGF-A mRNA, can effectively promote angiogenesis, and provides a reliable guarantee for research on medicines having the activity of promoting angiogenesis for treating microcirculatory disturbance diseases such as cerebral infarction, myocardial infarction, and lower limb ischemia.

IPC Classes  ?

  • C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
  • C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
  • C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
  • C07H 1/00 - Processes for the preparation of sugar derivatives
  • A61P 9/00 - Drugs for disorders of the cardiovascular system
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
  • C07C 69/16 - Acetic acid esters of dihydroxylic compounds
  • C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups